119 related articles for article (PubMed ID: 7557657)
1. Investigation of activated prothrombin complex concentrate as potential hirudin antidote in animal models.
Diehl KH; Römisch J; Hein B; Jessel A; Ronneberger H; Pâques EP
Haemostasis; 1995; 25(4):182-92. PubMed ID: 7557657
[TBL] [Abstract][Full Text] [Related]
2. A recombinant hirudin (IK-HIR02) in healthy volunteers. I. Effects on coagulation parameters and bleeding time.
Schenk JF; Glusa E; Radziwon P; Butti A; Markwardt F; Breddin HK
Haemostasis; 1996; 26(3):140-9. PubMed ID: 8738588
[TBL] [Abstract][Full Text] [Related]
3. Prothrombin conversion intermediate effectively neutralizes toxic levels of hirudin.
Nowak G; Bucha E
Thromb Res; 1995 Nov; 80(4):317-25. PubMed ID: 8585044
[TBL] [Abstract][Full Text] [Related]
4. Laboratory assays for the evaluation of recombinant hirudin.
Walenga JM; Hoppensteadt D; Koza M; Wallock M; Pifarre R; Fareed J
Haemostasis; 1991; 21 Suppl 1():49-63. PubMed ID: 1894197
[TBL] [Abstract][Full Text] [Related]
5. Some objective considerations for the neutralization of the anticoagulant actions of recombinant hirudin.
Fareed J; Walenga JM; Pifarre R; Hoppensteadt D; Koza M
Haemostasis; 1991; 21 Suppl 1():64-72. PubMed ID: 1894198
[TBL] [Abstract][Full Text] [Related]
6. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes.
Flather MD; Weitz JI; Yusuf S; Pogue J; Sussex B; Campeau J; Gill J; Schuld R; Joyner CD; Morris AL; Lai C; Théroux P; Marquis JF; Chan YK; Venkatesh G; Jessel A
Eur Heart J; 2000 Sep; 21(17):1473-81. PubMed ID: 10952840
[TBL] [Abstract][Full Text] [Related]
7. Influence of recombinant hirudin on tissue-factor-induced activation of coagulation in rabbits.
Kouz J; Czech J; Nicolay U; Dickneite G
Haemostasis; 1996; 26(4):179-86. PubMed ID: 8872128
[TBL] [Abstract][Full Text] [Related]
8. DDAVP reduces bleeding during continued hirudin administration in the rabbit.
Bove CM; Casey B; Marder VJ
Thromb Haemost; 1996 Mar; 75(3):471-5. PubMed ID: 8701410
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effect of hirudin on thrombosis induced by prothrombin complex concentrates.
Klöcking HP; Schulze-Riewald H; Markwardt F
Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):106-9. PubMed ID: 2459002
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the antithrombotic effect of the new recombinant hirudin HBW 023 and heparin in small arteries and veins.
Zhang B; Wieslander JB
Microsurgery; 1996; 17(2):89-96. PubMed ID: 8914063
[TBL] [Abstract][Full Text] [Related]
11. Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumab.
Honickel M; Treutler S; van Ryn J; Tillmann S; Rossaint R; Grottke O
Thromb Haemost; 2015 Apr; 113(4):728-40. PubMed ID: 25567155
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the effects of the thrombin inhibitor r-hirudin in four animal models of neointima formation after arterial injury.
Gerdes C; Faber-Steinfeld V; Yalkinoglu O; Wohlfeil S
Arterioscler Thromb Vasc Biol; 1996 Oct; 16(10):1306-11. PubMed ID: 8857929
[TBL] [Abstract][Full Text] [Related]
13. A direct thrombin inhibitor studied by dynamic whole blood clot formation. Haemostatic response to ex-vivo addition of recombinant factor VIIa or activated prothrombin complex concentrate.
Sørensen B; Ingerslev J
Thromb Haemost; 2006 Oct; 96(4):446-53. PubMed ID: 17003921
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamic and safety results of PEG-Hirudin in healthy volunteers.
Esslinger HU; Haas S; Maurer R; Lassmann A; Dübbers K; Müller-Peltzer H
Thromb Haemost; 1997 May; 77(5):911-9. PubMed ID: 9184402
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis.
Martin AC; Le Bonniec B; Fischer AM; Marchand-Leroux C; Gaussem P; Samama CM; Godier A
Int J Cardiol; 2013 Oct; 168(4):4228-33. PubMed ID: 23928345
[TBL] [Abstract][Full Text] [Related]
16. Haemostyptic effects of batroxobin with regard to hirudin treatment.
Markwardt F; Kaiser B; Richter M
Thromb Res; 1992 Dec; 68(6):475-82. PubMed ID: 1341058
[TBL] [Abstract][Full Text] [Related]
17. Antithrombin effects of native and recombinant hirudins.
Markwardt F; Stürzebecher J; Glusa E
Biomed Biochim Acta; 1990; 49(5):399-404. PubMed ID: 2271010
[TBL] [Abstract][Full Text] [Related]
18. Additive effect of the combined administration of low molecular weight heparin and recombinant hirudin on thrombus growth in a rabbit jugular vein thrombosis model.
Biemond BJ; Levi M; Nurmohamed MT; Büller HR; ten Cate JW
Thromb Haemost; 1994 Sep; 72(3):377-80. PubMed ID: 7855787
[TBL] [Abstract][Full Text] [Related]
19. Reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat-tail bleeding model and lack of effect on assays of coagulation.
van Ryn J; Schurer J; Kink-Eiband M; Clemens A
Anesthesiology; 2014 Jun; 120(6):1429-40. PubMed ID: 24714118
[TBL] [Abstract][Full Text] [Related]
20. Thrombotic safety of prothrombin complex concentrate (Beriplex P/N) for dabigatran reversal in a rabbit model.
Herzog E; Kaspereit FJ; Krege W; Doerr B; van Ryn J; Dickneite G; Pragst I
Thromb Res; 2014 Sep; 134(3):729-36. PubMed ID: 25084749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
